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Abstract
OBJECTIVES: /st> To study the expression, regulation and function of the histone methyltransferase
enhancer of zeste homologue 2 (EZH2) in synovial fibroblasts (SF) from patients with rheumatoid
arthritis (RA) and osteoarthritis (OA). METHODS: /st> SF were obtained from RA and OA patients
undergoing joint surgery. Expression levels were assessed by quantitative real-time PCR and western
blot. Kinase inhibitors and reporter gene assays were employed to study signalling pathways. Functional
analyses included EZH2 overexpression by plasmid transfection and gene silencing by small interfering
RNA. Chromatin immunoprecipitation assay was used to analyse histone methylation within distinct
promoter regions. RESULTS: /st> By studying the expression and function of EZH2 in SF the authors
found that EZH2 is overexpressed in rheumatoid arthritis synovial fibroblasts (RASF) and further
induced by tumour necrosis factor alpha through the nuclear factor kappa B and Jun kinase pathways.
As a target gene of EZH2 the authors identified secreted frizzled-related protein 1 (SFRP1), an inhibitor
of Wnt signalling, which is associated with the activation of RASF, and show that SFRP1 expression
correlates with the occupation of its promoter with activating and silencing histone marks.
CONCLUSIONS: /st> These data strongly suggest that the chronic inflammatory environment of the
RA joint induces EZH2 and thus might cause changes in the epigenetic programmes of SF.
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 Abstract 
 
Objectives 
To study expression, regulation and function of the histone methyltransferase EZH2 in synovial 
fibroblasts (SF) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). 
 
Methods 
 SF were obtained from RA and OA patients undergoing joint surgery. Expression levels were 
assessed by quantitative real time PCR and Western blot. Kinase inhibitors and reporter gene assays 
were employed to study signalling pathways. Functional analyses included EZH2 overexpression by 
plasmid transfection and gene silencing by siRNA. Chromatin immunoprecipation assay was used to 
analyse histone methylation within distinct promoter regions. 
 
Results 
By studying expression and function of EZH2 in SF we found that EZH2 is overexpressed in RASF 
and further induced by tumour necrosis factor alpha through the NF-B and Jun kinase pathways. As a 
target gene of EZH2 we identified secreted frizzled related protein (SFRP)1, an inhibitor of Wnt 
signalling, which is associated with the activation of RASF, and show that SFRP1 expression 
correlates with the occupation of its promoter with activating and silencing histone marks.  
 
Conclusions 
Our data strongly suggest that the chronic inflammatory environment of the RA joint induces EZH2 
and, thus, might cause changes in the epigenetic programmes of SF. 
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Introduction 
Rheumatoid arthritis (RA) is an inflammatory disorder characterized by the progressive destruction of 
joints and bones. The pathogenesis of RA is still not completely understood so far; however, within 
the inflamed and hyperplastic synovium of RA patients, synovial fibroblasts (RASF) have been 
identified as important mediators that promote ongoing inflammation and destruction. These cells 
show an aggressive phenotype, which is characterized by the production of inflammatory mediators 
and matrix-degrading enzymes, activation of signalling pathways, and by the dysregulation of 
oncogenes and tumour suppressors [1-2]. 
Efforts to investigate the relationship of human diseases and epigenetics - defined as changes in gene 
expression that might be inherited over generations of cells but are not due to an alteration of the 
underlying nucleotide sequence - have been growing exponentially in recent years [3]. Whereas most 
of these studies have been undertaken in the field of cancer research, epigenetics might also provide an 
important concept for the pathogenetic understanding of autoimmune disorders such as RA. In RASF, 
epigenetic alterations have been investigated on the level of histone acetylation [e.g. 4, 5-6] and DNA 
methylation [7]. In contrast, histone methylation has not been studied yet in RASF.  
Depending on the methylated position, the methylation of histones can be associated with active or 
inactive chromatin regions. The trimethyl mark on histone 3 lysine 27 (H3K27me3) is generally 
connected with transcriptionally silenced genes. It is generated by the histone methyltransferase 
Enhancer of Zeste Homologue (EZH)2, the catalytic subunit of the polycomb repressor complex 
(PRC)2  that adds up to three methyl groups to H3K27 of genes designated for silencing [8-9]. 
Important targets of the PRCs include developmental genes, e.g. the transcription factors of the 
homeobox (HOX) gene family, or elements of signal transduction pathways such as the wingless-type 
MMTV integration site (Wnt) signalling  [10-11], which plays an important role in joint development 
and has been implicated in the pathogenesis of inflammatory arthropathies [12].  
To address the question whether RASF show epigenetic changes on the level of histone methylation 
and whether these changes might contribute to their intrinsic activation, we studied the role of EZH2 
in RASF.  
Methods 
 
A detailed Methods section is provided in a supplementary file, available online only. 
 
Patient samples/Cell culture 
Synovial tissue samples were obtained during joint surgery from RA (n=39) and osteoarthritis (OA, 
n=22) patients.  Fibroblast cultures were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). For stimulation experiments, cells were 
serum-starved and stimulated with 10ng/ml tumour necrosis factor alpha (TNFα; R&D Systems, 
Abingdon, UK) in presence or absence of kinase inhibitors.  
 
Quantitative real-time PCR (qPCR) 
 Messenger RNA expression was quantified by TaqMan or SYBR green real-time PCR on the ABI 
Prism 7700 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland; primer 
sequences: see supplementary table S1, available online only). Data were analysed by the comparative 
Ct method with 18S rRNA employed as endogenous control.  
 
SDS-PAGE and Western blot 
For Western blot mouse-anti-EZH2 (Cell Signalling Technology), mouse anti-H3K27me3, rabbit anti-
Histone 3, rabbit anti-secreted frizzled-related protein 1 (sFRP-1) (all from Abcam), and mouse anti-α-
Tubulin (Sigma-Aldrich, Buchs, Switzerland and Abcam, Cambridge, UK) antibodies were used. 
Horseradish peroxidase-labelled species specific secondary antibodies (Jackson ImmunoResearch, 
Newmarket, Suffolk, UK) and enhanced chemiluminescence (GE Healthcare, Glattbrugg, Switzerland) 
were utilised for detection, and protein expression was quantified with Alpha Imager software. 
 
Immunohistochemistry  
To show expression of EZH2 in vivo, formalin-fixed paraffin embedded tissue sections were stained 
with mouse anti-EZH2 (BD Biosciences, Allschwil, Switzerland) and mouse anti-vimentin or mouse 
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anti-CD68 (Dako, Baar, Switzerland) antibodies to demonstrate localization to fibroblasts and 
macrophages. 
 
 
Plasmid construction 
The coding sequence of EZH2 was cloned into the pcDNA3.1(+) vector (Invitrogen, basel, 
Switzerland). A part of the EZH2 promoter (-1095 to +48, as described in [13]) and the GAPDH 
promoter (-1087 to -24) were cloned into pGL3basic and pRL (Promega, Dübendorf, Switzerland).  
 
Reporter gene assay 
Using Nucleofector technology (Amaxa, Cologne, Germany) RASF were transfected with 0.5μg 
pRL_GAPDH and 2μg pGL3basic_EZH2prom (wildtype or mutated), serum-starved and stimulated 
with TNFα (10ng/ml) for 24h. Firefly luciferase activity was measured with the Dual Luciferase 
Reporter Assay System (Promega) and normalized to the activity of Renilla luciferase. 
 
Overexpression and gene silencing 
RASF and OASF were transfected (Amaxa Nucleofection) with 1.5μg pcDNA_EZH2 or 10pmol 
siRNA (Qiagen, Hombrechtikon, Switzerland). Empty vector or AllStars Negative Control siRNA 
(Qiagen), respectively, served as controls. After 72h or 96h cells were harvested and gene 
overexpression or knockdown was analysed by qPCR and Western blot.  
 
sFRP-1 enzyme-linked immunosorbent assay (ELISA) 
To measure sFRP-1 in cell culture supernatants a sandwich ELISA was developed utilizing goat anti-
sFRP-1 (R&D Systems) as capture antibody, rabbit anti-sFRP-1 (Abcam) as detection antibody and 
horseradish peroxidase-labelled goat anti-rabbit-IgG antibody (Jackson) together with 3,3’,5,5’-
Tetramethylbenzidin for colour development.  
 
Chromatin immunoprecipation assay 
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SF were fixed with 1% formaldehyde and lysed. Chromatin was sheared by sonication and pre-cleared 
with normal rabbit serum (Jackson) and Protein A beads (Upstate/Millipore, Zug, Switzerland). For 
ChIP, 1 to 2 μg of antibody (anti-Histone 3, anti-H3K4me3 (both from Abcam), anti-H3K27me3 (Cell 
Signaling Technology, Danvers, MA, USA) or normal rabbit IgG (Santa Cruz, Heidelberg, Germany)) 
was added. Chromatin was precipitated with Protein A beads, washed, eluted, reverse-crosslinked, 
digested with Proteinase K and analysed by qPCR. 
 
Statistics 
For statistical analysis GraphPad Prism 5.0 software was used. Values are presented as mean±SD. A p 
value less than 0.05 was considered significant.  
 Results 
 
EZH2 is constitutively overexpressed in RASF. 
The histone methyltransferase EZH2 is associated with the epigenetic silencing of genes and has been 
found to be overexpressed in various cancers [14]. Since RASF share many pathogenetic features with 
malignant cells, including alterations in the regulation of the cell cycle, adhesive properties, invasion 
to and consecutive destruction of surrounding tissues [15], we investigated the expression of EZH2 
both in SF and in tissue sections from RA patients.  
In vitro, we found a constitutively higher expression of EZH2 mRNA in RASF as compared to OASF 
(Figure 1A). These findings were confirmed on the protein level, showing an increased expression of 
EZH2 in RASF as analysed by Western blot (Figure 1B). Furthermore, by using synovial tissue 
specimen of RA and OA patients, we found that EZH2 is expressed in vivo as well, both in fibroblasts 
(stained for the mesenchymal marker vimentin, Figure 1C) and macrophages (CD68-positive cells, 
Figure 1D). These data indicate that EZH2 might play a role in the epigenetic regulation of genes in 
RA. 
 
Stimulation with TNFα induces EZH2. 
TNFα is a major inflammatory mediator in the pathogenesis of RA and inflammation has already been 
associated with epigenetic changes [16-17]. We thus addressed whether the addition of TNFα might 
modulate the expression levels of EZH2 in SF. As shown in Figure 2, stimulation of cells with TNFα 
increased the expression of EZH2 mRNA both in RASF and in OASF with the strongest effect 
observed after 48h (Figure 2A). Similar results were obtained by Western blot analysis for EZH2 
protein (Figure 2B). As the catalytic subunit within the PRC2, EZH2 exerts its functional activity only 
in connection with the other PRC2 components [18]. We therefore measured the expression of other 
PRC2 constituents, i.e. suppressor of zeste homologue 12 (SUZ12) and embryonic ectoderm 
development (EED) (online Supplementary Figure S1).  
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The upregulation of EZH2 in SF does not correlate with global H3K27me3. 
Due to the primordial function of EZH2 as a distinct methyltransferase that targets lysine 27 on 
histone 3, its upregulation might lead to a concomitant increase in the methylation of its substrate. By 
addressing the global state of H3K27 trimethylation in RASF compared to OASF by Western blot, 
however, no differences in H3K27me3 could be detected between patient groups or after stimulation 
with TNFα (Figures 2C-D).  
 
TNFα induced upregulation of EZH2 is mediated through JNK and IKK2-dependent pathways. 
In a next step we elucidated the intracellular mechanisms involved in the TNFα induced upregulation 
of EZH2 by performing kinase inhibition experiments for the major downstream signalling cascades 
of TNFα, i.e. MAP kinases and NF-B-pathways. The inhibition of IKK-2 (inhibitor of nuclear factor 
κB kinase subunit beta) completely abrogated the induction of EZH2 mRNA in RASF and OASF 
(Figure 3A), whereas the inhibition of Jun kinase (JNK) resulted in a partial reduction of EZH2 
induction (Figure 3B). Inhibition of the p38 MAP kinase did not show any effects on EZH2 expression 
(Figure 3C).  
 
E2F acts as direct upstream transcriptional activator of EZH2. 
It has already been shown that the transcription factor E2F is a direct upstream regulator of EZH2 in 
response to serum stimulation [13]. Moreover, it has been reported that its direct inhibitor pRb is 
constitutively inactivated in RASF [19]. In order to investigate whether the TNFα induced expression 
of EZH2 might be due to the activation of E2F, we performed reporter gene assays with luciferase 
vectors containing the EZH2 promoter with the wildtype or a mutated binding site for E2F (Figure 
3D). TNFα stimulation resulted in a higher activity of the EZH2 promoter as compared to 
unstimulated control. This effect was partially inhibited by mutation of the E2F binding site, indicating 
a direct interaction between E2F and the EZH2 promoter.  
 
sFRP-1 is targeted by EZH2 in SF. 
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In the rheumatoid synovium the expression of agonists and antagonists of Wnt signalling was found to 
be dysregulated, among them the Wnt inhibitor sFRP-1 [20]. Since elements of the Wnt pathway 
comprise known targets of EZH2 [10-11], we investigated whether EZH2 might be involved in the 
silencing of this specific target gene in RASF. EZH2 overexpression by transfection reduced the levels 
of SFRP1 mRNA and protein in SF (Figures 4A-B). Conversely, transfection of RASF with siRNA 
targeting EZH2 resulted in a significant increase of SFRP1 mRNA at 72h (Figure 4C).  
 
sFRP-1 is differentially expressed in RASF and OASF and is strongly repressed by TNFα. 
To test the hypothesis that SFRP1 might be epigenetically silenced in RASF, its differential expression 
between RASF and OASF was assessed. As shown in Figure 5A the expression of SFRP1 mRNA was 
significantly reduced in RASF compared to OASF. Figures 5B and C emphasize that this was also true 
for the expression of sFRP-1 protein with RASF reaching only half the sFRP-1 expression observed in 
OASF.  
Since EZH2 is upregulated by TNFα, and sFRP-1 appeared to be a target of EZH2-mediated gene 
silencing, we asked whether TNFα also has an impact on the expression of sFRP-1. As shown in 
Figures 5D and E stimulation of SF with TNFα strongly decreased the expression of SFRP1 mRNA 
and protein after 48h. Yet, a direct link between the TNF induced upregulation of EZH2 and the 
downregulation of SFRP1 remains presumptive at this moment. 
 
Activating and silencing chromatin marks of the SFPR1 gene promoter are different between RASF 
and OASF.  
To prove that SFRP1 is subject to EZH2 mediated silencing we performed chromatin 
immunoprecipitation (ChIP) analysis. Chromatin precipitated with antibodies against histone 3, 
H3K4me3 and H3K27me3 was analysed for enrichment in three regions of the SFRP1 promoter 
(upstream, downstream and at the transcription start site (TSS), Figure 6A). In general, the differences 
in H3K4me3 and H3K27me3 occupation of the SFRP1 promoter between RASF and OASF were 
strongest in region 3. Whereas the activating methylation of H3K4 was reduced in RASF, the 
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repressive H3K27 trimethylation was increased (Figure 6B). The trends observed in promoter regions 
1 and 2 were similar but weaker than in region 3.  
Since we observed a strong variability of H3K4me3 and H3K27me3 at the SFRP1 promoter between 
cells from different patients, we analysed whether this might correlate with the expression of SFRP1. 
As shown in Figure 6C, a strong positive correlation between H3K27me3 and the ΔCt value of SFRP1 
was found (Pearson’s r=0.634). On the other hand, a high H3K4me3/H3 ratio correlated with a low 
SFRP1 ΔCt value and thus higher mRNA expression levels (r=-0.845). These data indicate that SFRP1 
expression in RASF is reduced due to decreased H3K4me3 and increased H3K27 methylation in its 
promoter. 
We also analysed other Wnt inhibitors, including Dickkopf-1 (DKK1) and SFRP2-5, but could only 
detect significant expression differences for SFRP2 (online Supplementary Figure S2). Although there 
was a general trend towards a correlation between H3K4me3 and H3K27me3 occupation of the 
promoters and Wnt inhibitor expression levels, there was not such a distinct pattern of expression 
correlating with both histone methylation marks as for SFRP1. These data suggest that the differential 
regulation by H3K4/H3K27 methylation in OASF and RASF is unique to SFRP1. 
Discussion 
 
In this study we focused on the expression and function of the histone methyltransferase EZH2 in 
synovial fibroblasts of RA patients and found that a) EZH2 is overexpressed in RASF as compared to 
OASF; b) expression of EZH2 is induced by TNF involving NF-B and MAP-kinase pathways; and 
c) SFRP1 is a direct target gene of EZH2, whose expression pattern correlates with the occupation of 
activating and inactivating histone methylation marks in its promoter region.  
 
Whereas the status of histone methylation and its respective mediators has not been assessed in RA so 
far, EZH2 has been found overexpressed in different cancers and, in malignancies involving the 
prostate and breast, it has been proposed as a marker of disease progression and metastatic potential 
[21-22]. Likewise, the behaviour of cells within the rheumatoid synovium has been compared to the 
growth of an invasive tumour from which synovial fibroblasts actively invade and destroy the articular 
cartilage [23-25]. Consistent with the findings from cancer tissues, we showed in the present study that 
the expression levels of EZH2 are increased in RASF and, moreover, that these levels can be further 
enhanced by TNFα stimulation. We could link this effect to the intracellular activation of NF-κB, JNK 
and E2F-Rb pathways, all of which represent major signalling cascades involved in the activation of 
SF.  
Despite the induction of EZH2 expression, we could not detect changes of global H3K27me3 in 
response to TNFα. One thus could speculate that EZH2 is specifically targeted to certain chromatin 
areas so that its activity is eventually not reflected in global changes of H3K27me3. Such specific 
targeting of local chromatin areas has already been suggested by others. De Santa et al. could 
demonstrate that in macrophages the LPS-induced expression of Jmjd3, i.e. the demethylase for 
H3K27me3, did not cause alterations in global methylation of H3K27 [16]. In a next step we thus 
focused on potential target genes that might show local methylation changes in their promoters and 
identified SFRP1 as a direct target of EZH2. Decreased expression of sFRP-1 within the rheumatoid 
synovium has already been described by Imai et al. [20]; here, we identified the distinct epigenetic 
mechanisms of this downregulation and unravelled the signalling pathways in RASF in vitro.   
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 sFRP-1 inhibits Wnt signalling by directly binding to Wnts and is thus believed to antagonize both the 
canonical and non-canonical pathways [26]. Inactivation of SFRP1 by DNA methylation has been 
described among the early changes occurring in the development of colorectal cancer [27]. In RA, 
canonical Wnt signalling has been shown to participate in the activation of RASF through the 
regulation of cytokines, matrix metalloproteinase (MMP)3 and production of extracellular matrix 
molecules [28-29]. Furthermore, the RA synovium has been found to contain higher levels of Wnt1, 
Wnt5A, and Wnt10B than OA or normal synovium [20, 30]. It is thus highly suggestive that, by 
producing considerably less amounts of sFRP-1, the RASF is turned even more responsive to Wnt 
proteins in the synovial tissue. Inhibition of Wnt agonists or upregulation of Wnt antagonists, e.g. by 
interfering with epigenetic mechanisms, therefore appears to be favourable in the pathogenesis of RA 
regarding the attenuation of the invasive and destructive potential of RASF. On the other hand, bone 
erosions can be inhibited by blocking the Wnt inhibitor DKK1 which was found to enhance 
osteoclastogenesis and repress bone formation by osteoblasts [31-32]. The question thus arises 
whether the influence of Wnt signalling on joint destruction is cell type dependent or defined by the 
different modes of action of DKK1 and SFRPs. 
Our data indicate that the epigenetic landscape of the SFRP1 promoter in RASF is changed towards a 
transcription-inhibiting state. Overexpression of the H3K27-methyltransferase EZH2 led to reduced 
levels of SFRP1 and, conversely, silencing of EZH2 to increased SFRP1 levels. By comparing RASF 
with OASF, we could observe increased H3K27me3 with a concomitant decrease of H3K4me3. 
H3K4me3 and H3K27me3 are known to co-localise in bivalent domains which, depending on the type 
of cells, cause genes to tend towards a rather repressed or activated state [33-34]. Ke et al. showed that 
genes carrying H3K4me3 are more expressed than those carrying both H3K4me3 and H3K27me3, 
which in turn are more highly expressed than those carrying only H3K27me3 [34]. Indeed, we have 
demonstrated that the SFRP1 promoter in SF contains such a bivalent domain and that the expression 
of SFRP1 correlates with both methyl marks. 
Our experiments suggest the following model of SFRP1 silencing in SF in the chronically inflamed 
RA joint. Continuous exposure to TNF and other inflammatory mediators (see online Supplementary 
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Figure S3) might lead to alterations in epigenetic programmes, e.g. through the induction of EZH2 
expression. Trimethylation of lysine 27 of histone 3 and the loss of H3K4 trimethylation within the 
promoter regions might implement the TNF induced silencing of SFRP1 so that it could persist even 
outside the inflammatory environment. Whereas only a weak correlation between the EZH2 
expression and SFRP1 expression was found, the levels of SFRP1 mRNA and methylation status of its 
promoter could be strongly correlated. In cell culture, RASF escape from the ongoing exposure to 
inflammatory cytokines thus probably leading to a relative normalization of the EZH2 levels. This 
could explain the proportionally moderate increase of basal EZH2 expression in RASF when 
compared to OASF as observed in the present study. These basal expression levels of EZH2, however, 
might already be sufficient to maintain the epigenetic memory of the cells by copying the methyl mark 
on the SFRP1 gene during replication. Whether the addition of TNFantagonists in patients might have 
a similar effect and, over time, even reverse the epigenetic phenotype is speculative. Since our data 
suggest an analogous role of EZH2 in RASF and in cancer cells, it might be of interest for further 
studies to investigate EZH2 as potential marker for disease activity, in particular for patients with 
ongoing joint destruction despite treatment with TNFantagonists. 
 
In summary, we addressed here for the first time histone methylation in RASF and found an 
overexpression of the histone methyltransferase EZH2 thus leading to alterations in the Wnt signalling 
pathway by downregulation of the tumour suppressor gene SFRP1.  
 
 
 Acknowledgements 
 
We thank Dr. Britta Maurer and Emmanuel Karouzakis for valuable discussions. This work was 
supported by the Swiss National Science Foundation (SNSF-32000-116842), Schwyzer Foundation, 
Autocure FP6, Masterswitch FP7 and IAR Epalinges programmes. 
 
Disclaimer 
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of 
all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to 
the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in ARD and any 
other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our 
licence (http://ARD.bmjjournals.com/ifora/licence.pdf). 
 14
References 
 
1 Pap T, Muller-Ladner U, Gay RE, et al. Fibroblast biology. Role of synovial fibroblasts in the 
pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2:361-367. 
2 Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin 
Rheumatol 2008;22:239-252. 
3 Hirst M, Marra MA. Epigenetics and human disease. Int J Biochem Cell Biol 2009;41:136-146. 
4 Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of 
autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. 
Arthritis Rheum 2004;50:3365-3376. 
5 Huber LC, Brock M, Hemmatazad H, et al. Histone deacetylase/acetylase activity in total synovial 
tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007;56:1087-
1093. 
6 Maciejewska-Rodrigues H, Karouzakis E, Strietholt S, et al. Epigenetics and rheumatoid arthritis: 
the role of SENP1 in the regulation of MMP-1 expression. J Autoimmun 2010;35:15-22. 
7 Karouzakis E, Gay RE, Michel BA, et al. DNA hypomethylation in rheumatoid arthritis synovial 
fibroblasts. Arthritis Rheum 2009;60:3613-3622. 
8 Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group 
silencing. Science 2002;298:1039-1043. 
9 Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al. Histone methyltransferase activity 
associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 
2002;16:2893-2905. 
10 Bracken AP, Dietrich N, Pasini D, et al. Genome-wide mapping of Polycomb target genes unravels 
their roles in cell fate transitions. Genes Dev 2006;20:1123-1136. 
11 Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by Polycomb in human 
embryonic stem cells. Cell 2006;125:301-313. 
12 Schett G, Zwerina J, David JP. The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 
2008;4:473-480. 
 15
13 Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for 
proliferation and amplified in cancer. EMBO J 2003;22:5323-5335. 
14 Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat 
Res 2008;647:21-29. 
15 Davis LS. A question of transformation: the synovial fibroblast in rheumatoid arthritis. Am J Pathol 
2003;162:1399-1402. 
16 De Santa F, Totaro MG, Prosperini E, et al. The histone H3 lysine-27 demethylase Jmjd3 links 
inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007;130:1083-1094. 
17 Hahn MA, Hahn T, Lee DH, et al. Methylation of polycomb target genes in intestinal cancer is 
mediated by inflammation. Cancer Res 2008;68:10280-10289. 
18 Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev 
Mol Cell Biol 2009;10:697-708. 
19 Bradley K, Scatizzi JC, Fiore S, et al. Retinoblastoma suppression of matrix metalloproteinase 1, 
but not interleukin-6, through a p38-dependent pathway in rheumatoid arthritis synovial fibroblasts. 
Arthritis Rheum 2004;50:78-87. 
20 Imai K, Morikawa M, D'Armiento J, et al. Differential expression of WNTs and FRPs in the 
synovium of rheumatoid arthritis and osteoarthritis. Biochem Biophys Res Commun 2006;345:1615-
1620. 
21 Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in 
progression of prostate cancer. Nature 2002;419:624-629. 
22 Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes 
neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11611. 
23 Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361. 
24 Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in 
rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52 
Suppl 1:S39-47. 
25 Fassbender HG, Seibel M, Hebert T. Pathways of destruction in metacarpal and metatarsal joints of 
patients with rheumatoid arthritis. Scand J Rheumatol 1992;21:10-16. 
 16
 17
26 Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 
2003;116:2627-2634. 
27 Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive 
WNT signaling in colorectal cancer. Nat Genet 2004;36:417-422. 
28 Sen M, Chamorro M, Reifert J, et al. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid 
synoviocyte activation. Arthritis Rheum 2001;44:772-781. 
29 Sen M, Reifert J, Lauterbach K, et al. Regulation of fibronectin and metalloproteinase expression 
by Wnt signaling in rheumatoid arthritis synoviocytes. Arthritis Rheum 2002;46:2867-2877. 
30 Sen M, Lauterbach K, El-Gabalawy H, et al. Expression and function of wingless and frizzled 
homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A 2000;97:2791-2796. 
31 Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 
2007;13:156-163. 
32 Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss 
during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010;69:2152-2159. 
33 Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental 
genes in embryonic stem cells. Cell 2006;125:315-326. 
34 Ke XS, Qu Y, Rostad K, et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 
trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS ONE 2009;4:e4687. 
35 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat 
Protoc 2008;3:1101-1108. 
 
 
 
Legends to figures 
 
Figure 1 EZH2 expression in RASF and synovial tissue  
A. EZH2 mRNA (relative to 18S rRNA) was increased by 1.5-fold in RASF (ΔCt: 7.61±0.63, n=15) 
as compared to OASF (ΔCt: 8.16±0.5, n=12) with higher Ct values representing lower expression 
levels [35]. B. EZH2 protein was increased by 1.5-fold in RASF (n=14) as compared to OASF (n=10) 
(ratio EZH2/α-tubulin RASF: 0.47±0.15, OASF: 0.32±0.1, p<0.05). C and D. In vivo, EZH2 (blue) is 
expressed both by fibroblasts (C, Vimentin+ cells, red, n=2 OA, n=2 RA) as well as by macrophages 
(D, CD68+ cells, red, n=2 OA, n=4 RA). As a smaller inset the respective IgG control is depicted in 
100x magnification.  
 
Figure 2 Effect of TNFα on EZH2 and H3K27me3 
A. EZH2 mRNA was significantly induced by TNFα in OASF (2.21±0.55-fold and 3.13±0.94-fold, 
n=6) and RASF (2.93±1 and 3.17±1.12-fold, n=7) after 24h and 48h, respectively. The dashed line 
represents the unstimulated control for each time point. B. EZH2 protein was induced by TNFα in 
OASF (2.2±0.8-fold) and RASF (2.1±1-fold) after 48h (p≤0.0001, n=14 and 15, respectively). C. 
Constitutive global H3K27me3 is not different in OASF and RASF (n=3 each). D. Global H3K27me3 
in TNFα stimulated OASF and RASF (n=4 each) after 48h is not changed. * p<0.05, ** p<0.005, *** 
p<0.001. 
 
Figure 3 Regulation of TNFα induced EZH2 expression  
A. Induction of EZH2 mRNA was abrogated by pretreating SF with the NF-κB pathway inhibitor sc-
514 (IKK2i) (n=4 each). B. Induction of EZH2 mRNA was reduced by pretreating SF with the JNK 
inhibitor II (JNKi) (by 47±17% in RASF and 81±4% in OASF, n=4 each). C. Induction of EZH2 
mRNA was not affected by pretreating SF with the p38 inhibitor SB203580 (p38i) (n=4 each). D. In 
reporter gene assays, the relative activity of the EZH2 promoter (firefly luciferase normalized to 
Renilla luciferase) in RASF (n=5) was increased after 24h TNFα stimulation by 2.1±0.6-fold. 
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Mutation of the E2F binding site reduced the EZH2 promoter activation by TNFα to 1.7±0.7-fold. * 
p<0.05, ** p<0.005, *** p<0.001. 
 
Figure 4 Overexpression of EZH2 in RASF reduces sFRP-1 expression 
A. Overexpression of EZH2 decreased SFRP1 mRNA by 15±17% (72h) and 18±9% (96h). B. sFRP-1 
protein in cell culture supernatants was reduced from 689±216 pg/ml to 507±56 pg/ml (minus 
21.6±22.8%) after 72h and from 1095±101 pg/ml to 836±150 pg/ml (minus 22.9±17.7%) after 96h of 
EZH2 transfection, as assessed by ELSIA. C. Knockdown of EZH2 resulted in a significant 
upregulation of SFRP1 mRNA by 15±11.7% at 72h.  
 
Figure 5 Constitutive and TNFα regulated expression of sFRP-1 in RASF and OASF 
A. SFRP1 mRNA (relative to 18S rRNA) was reduced by 86% in RASF (Ct: 7.1±2, n=15) as 
compared to OASF (Ct: 4.5±1.7, n=12). B. Western blot analysis showed strongly reduced levels of 
sFRP-1 protein in RASF (n=10) compared to OASF (n=7) (ratio sFRP-1/α-tubulin RASF: 0.31±0.18, 
OASF: 0.63±0.31, p<0.05). C. sFRP-1 levels in supernatants of RASF (566±354 pg/ml, n=10) were 
reduced by 56% compared to OASF (1285±845 pg/ml, n=7). D. SFRP1 mRNA levels were reduced 
by TNFα in RASF (by 85±6%, n=6) and OASF (by 82±7%, n=7) with the strongest effect after 48h. 
The dashed line represents the respective unstimulated control for each time point E. sFRP-1 protein 
expression was decreased after 48h of TNFα stimulation in RASF (by 36±19%) and OASF (by 
45±7%) (n=6 each, p≤0.005). * p<0.05, ** p<0.005, *** p<0.001 
 
Figure 6 ChIP analysis of the SFRP1 promoter in RASF and OASF 
A. Schematic representation of the SFRP1 promoter. Shaded areas represent CpG islands as calculated 
by MethPrimer (www.urogene.org/methprimer). “+1” indicates the transcription start site (TSS). 
Black boxes represent the three different amplicons for ChIP-qPCR (1: -750/-699 bp, 2: -100/-51 bp, 
3: +991/+1024 bp relative to TSS) B. qPCR analysis of chromatin from RASF (n=10) and OASF 
(n=7) ChIPed with rabbit IgG, anti-Histone 3, anti-H3K4me3 and anti-H3K27me3. To compare 
different patient samples, the ratio between the levels of the methylation mark and total histone 3 at 
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promoter regions was calculated. RASF showed a decreased trimethylation of H3K4 (ratio to H3: 
0.31±0.27, OASF: 0.66±0.32) and increased H3K27me3 (ratio to H3: 0.45±0.36, OASF: 0.22±0.08). 
C. ΔCt of SFRP1 mRNA in RASF (■) and OASF (▲) correlated negatively with the H3K4me3/H3 
ratio (right) and positively with the H3K27me3/H3 ratio (left) in region 3 of the SFRP1 promoter.  
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Supplementary Methods 
 
Patient samples/ Cell culture 
Synovial tissue samples were obtained during joint surgery from RA and osteoarthritis (OA) patients 
after they had given written informed consent for further use of their tissue for research purposes. 
Work with patient materials was approved by the local ethics committee. For fibroblast cultures, tissue 
specimen were digested with collagenase and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Fibroblasts from passages 4 to 9 were used. 
 
Stimulation experiments/ Inhibitor studies 
SF were starved for 16-24h in DMEM containing 0.5% FCS and stimulated with 10ng/ml TNF-α 
(R&D Systems). For kinase inhibition studies, SF were pre-incubated with sc-514 (50μM, IKK-2 
inhibitor), JNK Inhibitor II (20μM), p38 inhibitor SB203580 (10μM) (all from Sigma Aldrich) or 
DMSO alone for 1h before adding TNF-α. 
 
SDS-PAGE and Western blot 
Whole cell lysates were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to nitrocellulose or PVDF membranes. Membranes were blocked with 
5% milk or 2% horse serum in TBS-T and incubated with the following antibodies: mouse-anti-EZH2 
(Cell Signaling Technology), mouse-anti-H3K27me3, rabbit-anti-Histone 3, rabbit-anti-SUZ12, 
rabbit-anti-sFRP-1 (all from Abcam), sheep-anti-EED (R&D Systems), mouse-anti-α-Tubulin (Sigma-
Aldrich and Abcam). Horseradish peroxidase (HRP)-labelled species specific secondary antibodies 
(Jackson ImmunoResearch) and enhanced chemiluminescence (GE Healthcare) were utilised for 
detection, and protein expression was quantified with Alpha Imager software. 
 
Immunohistochemistry  
Formalin-fixed paraffin embedded tissue sections were deparaffinised and underwent antigen retrieval 
with 1mg/ml Trypsin for 25 min at 37°C (only for CD68 staining) and in 10mM citrate buffer (pH 6.0) 
for 30 min at 90°C. Unspecific binding was blocked by 5% goat serum in PBS (+1% BSA) before the 
sections were incubated with mouse-anti-EZH2 (BD Biosciences) or mouse IgG (Dako) (10μg/ml) 
over night at 4°C. Biotinylated secondary goat-anti-mouse antibody (Jackson ImmunoResearch), 
Vectastain ABC Kit for alkaline phosphatase and Vector Blue (Vector Laboratories) were used for 
detection. Subsequently, endogenous peroxidase was blocked with 3% H2O2 for 10 min before 
incubating with 5% goat serum in PBS (+1% BSA) for 1h. To show the expression of EZH2 in cells of 
mesenchymal origin (fibroblasts) or in macrophages, mouse-anti-vimentin or mouse-anti-CD68 
(2μg/ml, Dako) antibodies were applied over night at 4°C and detected using HRP-labelled goat-anti-
mouse antibody (for vimentin) or biotinylated goat-anti-mouse antibody and Vectastain Elite ABC Kit 
for HRP (for CD68) together with aminoethylcarbazole as chromogen. 
 
Plasmid construction 
The coding sequence of EZH2 was amplified from human cDNA and inserted into the pcDNA3.1(+) 
vector (Invitrogen) via the BamHI and XhoI restriction sites. A part of the EZH2 promoter (-1095 to 
+48, as described in [1]) and the GAPDH promoter (-1087 to -24) were amplified from human 
genomic DNA and cloned into pGL3basic and pRL (Promega), respectively, via the BglII and HindIII 
sites. The E2F binding site (+33 to +40) in the EZH2 promoter was mutated by site-directed 
mutagenesis in four positions. 
 
Transfection 
RASF and OASF were transfected with the Basic Nucleofector Kit for Primary Mammalian 
Fibroblasts (Amaxa) according to the manufacturer’s instructions. The medium was replaced 24h after 
transfection to remove floating cells.  
 
Reporter gene assay 
RASF were transfected with 0.5μg pRL_GAPDH and 2μg pGL3basic_EZH2prom or 
pGL3basic_EZH2prom_ΔE2F. After 24h in complete medium, cells were starved for 24h (DMEM + 
0.5% FCS) and stimulated with TNF-α (10ng/ml) for another 24h. Firefly luciferase activity was 
measured with the Dual Luciferase Reporter Assay System (Promega) and normalized to the activity 
of Renilla luciferase. 
 
sFRP-1 enzyme-linked immunosorbent assay (ELISA) 
To measure sFRP-1 in cell culture supernatants microwell plates were coated with goat-anti-sFRP-1 
antibody (0.5mg/ml, R&D Systems) in sodium carbonate buffer (pH 9.5) over night at 4°C (as in [2]). 
PBS with 0.05% Tween-20 was used for the washing between incubation steps. After coating, wells 
were blocked with 300μl reagent diluent (2% non-fat dry milk in PBS) for 1h at room temperature. 
Recombinant sFRP-1 (R&D Systems) was used to generate a standard curve (range: 0-10000 pg/ml) 
and incubated together with the undiluted cell culture supernatants for 2h at room temperature. For 
detection, rabbit-anti-sFRP-1 antibody (1:1000, Abcam) was added for 2h. HRP-labelled goat-anti-
rabbit-IgG antibody (1:5000, Jackson) was incubated for 1h and detection was performed with 
3,3’,5,5’-Tetramethylbenzidin. Colour development was stopped with 2N H2SO4 and absorbance was 
measured at 450 nm (with wavelength correction at 560 nm).  
 
Chromatin immunoprecipation assay 
Three million SF were fixed with formaldehyde solution for 10 min (see online Supplementary Table 
S2 for details of buffer compositions). Fixation was stopped by adding 200mM glycine. After washing 
the cells with PBS three times, lysis buffer was added. Chromatin was sheared by sonication to a size 
of 400-800 bp (Bandelin Sonopuls HD2070, 6 cycles of 10s sonication at 50% power and 1 min pause 
on ice) and 10% of the sample was removed as input control. Sonicated chromatin was diluted 1:10 
and pre-cleared for 4h by adding 10μl/ml normal rabbit serum (Jackson) and 20μl/ml Protein A beads 
(Upstate, 50% slurry in TE blocked with 1mg/ml BSA and 0.4mg/ml herring sperm DNA). Pre-
cleared chromatin was parcelled to aliquots, 1 to 2 μg of antibody (anti-Histone 3, anti-H3K4me3 
(both from Abcam), anti-H3K27me3 (Cell Signaling Technology) or normal rabbit IgG (Santa Cruz) 
was added and rotated over night at 4°C. Chromatin was precipitated with 40μl/ml Protein A beads for 
4h, washed with wash buffers I to III and finally two times TE buffer. Precipitated chromatin was 
eluted by incubating twice with elution buffer for 20 min, reverse cross-linked and digested with 
Proteinase K over night at 65°C and purified with the PCR purification kit (Qiagen). Samples were 
analysed by qPCR and normalized to the 10% input sample. Occupation of the GAPDH and MYOD 
promoters was measured as positive controls for H3K4me3 and H3K27me3, respectively. 
 
Statistics 
For statistical analysis GraphPad Prism 5.0 software was used. Values are presented as mean ± 
standard deviation. Data were analysed using Student’s t-test for parametric samples and the Mann-
Whitney test or Wilcoxon signed rank test for nonparametric samples, as well as Pearson’s correlation. 
A p-value < 0.05 was considered significant. Detailed information about which statistical test was used 
for individual experiments are provided in Supplementary Table S3.  
 
References for Supplementary Methods 
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2 Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in 
glaucoma elevates intraocular pressure. J Clin Invest 2008;118:1056-1064. 
 
 
Legends to Supplementary Figures 
 
Figure S1 Effect of TNF- on the PRC2 components EED and SUZ12 
A. SUZ12 and EED mRNAs were significantly induced by TNF-α in OASF (n=6) and RASF (n=7) 
after 24h and 48h. B. EED (n=5 OASF, n=8 RASF) and SUZ12 protein expression after 48h TNF-α 
stimulation.  SUZ12 protein was induced in OASF (2.6±2.2-fold, p=0.001, n=11) and RASF (1.8±0.8-
fold, p=0.0002, n=14). 
 
Figure S2 mRNA expression of different Wnt inhibitors and occupation of their promoters with 
H3K27me3 and H3K4me3 
A. Similar to SFRP1, the expression of SFRP2 was significantly reduced in RASF. Also, SFRP4, 
which showed the highest expression of all Wnt inhibitors measured (ΔCt RASF: 2.43±1.54, OASF: 
1.67±1.3), was reduced in RASF; the reduction observed, however, did not reach statistical 
significance. In contrast, DKK1 showed a trend towards higher expression in RASF. SFRP3 was only 
weakly expressed and levels of SFRP5 mRNA could not be detected (n.d.). B. The occupation of the 
SFRP2 promoter with H3K27me3 was comparable to that of SFRP1. The promoters of DKK1 and 
SFRP4 showed low levels of H3K27me3. The H3K27me3 occupation of the promoters for SFRP2, 
SFRP3 and SFRP5 tended to be higher in RASF than in OASF; these differences were not statistically 
significant. Interestingly, the activating H3K4me3 mark was absent at the SFRP3 and SFRP5 
promoters in both OASF and RASF, which may – at least in part – explain the low (SFRP3) or 
missing (SFRP5) mRNA expression of these Wnt inhibitors. In contrast, the DKK1 and SFRP4 gene 
promoters contained high levels of H3K4me3, most likely accounting for their high mRNA expression 
levels. However, different to SFRP1, we could not correlate H3K4me3/H3 and H3K27me3/H3 ratios 
of DKK1 and SFRP2-5 to their respective mRNA expression levels. H3K4me3 and H3K27me3 levels 
at the promoters of GAPDH and MYOD are shown as positive (GAPDH for H3K4me3, MYOD for 
H3K27me3) and negative controls (GAPDH for H3K27me3, MYOD for H3K4me3), respectively. 
(RASF: n=4-15, OASF: n= 4-12)  
 
Figure S3 Effect of interleukin-1 (IL-1) and toll-like receptor (TLR) ligands on the expression of 
EZH2 and SFRP1 
Similar to stimulation with TNF- treatment of RASF (n=5) with the TLR3 ligand poly(I:C) led to 
upregulation of EZH2 (A) and downregulation of SFRP1 (B) after 48h. Additionally, SFRP1 mRNA 
expression was reduced by stimulation with the TLR2 ligand Palmitoyl-Cys((RS)-2,3-
di(palmitoyloxy)-propyl)-OH (Pam3). IL-1 and the TLR4 ligand lipopolysaccharide (LPS) did not 
have an effect on the mRNA levels of EZH2 or SFRP1. The dashed line represents the unstimulated 
control. * p<0.05, ** p<0.005. 
 
 
Table S1 Primers for qPCR
gene expression analysis ChIP analysis
18S rRNA assay from Applied Biosystems (Cat. No. 4310893E) DKK1 TSS for 5’ - GTA TAA AGG CAG CCG CGG TG – 3’
DKK1 for 5’ - CCA GAC CAT TGA CAA CTA CCA G – 3’ DKK1 TSS rev 5’ - TCC CAG AGT CCT GAC TGC AG – 3’
DKK1 rev 5’ - TGC CGC ACT CCT CGT CCT C – 3’ GAPDH for 5’ - TCG ACA GTC AGC CGC ATC TTC – 3’
EZH2 for 5’ – AGT GTT ACC AGC ATT TGG AGG G – 3’ GAPDH rev 5’ - CTA GCC TCC CGG GTT TCT CT – 3’
EZH2 rev 5’ – CGG TGA GAG CAG CAG CAA AC – 3’ MYOD for 5’ - CCG CCT GAG CAA AGT AAA TGA G – 3’
EED for 5’ - GCA ATC CAG ACC TCT CTG GAG - 3’ MYOD rev 5’ - TGG GCA ACC GCT GGT TTG GAT – 3’
EED rev 5’ - CCA CTT TCT ATA CTG ACA GCG TC - 3’ SFRP1 up for (region 1) 5’ - CTT CCT GAA CCC CTG TTA GTT G – 3’
SFRP1 for 5' - TGA GGC CAT CAT TGA ACA TC - 3' SFRP1 up rev (region 1) 5’ - TCT AGC TGC GGT GCA GAC AG  – 3’
SFRP1 rev 5' - TCA TCC TCA GTG CAA ACT CG - 3' SFRP1 TSS for (region 2) 5’ - TGA CGG ACG TGG TAA CGA GTG – 3’
SFRP2 for 5’ - AGC GAC CAC CTC CTG CCA G – 3’ SFRP1 TSS rev (region 2) 5’ - AGC CAA TCA GCT CCC GGC G – 3’
SFRP2 rev 5’ - CAG GCT TCA CAT ACC TTT GGA G – 3’ SFRP1 down for (region 3) 5’ - CGT GAT TCC TAA GCG CGT CTG – 3’
SFRP3 for 5’ - CTA GTA ACG GAA ACT GTA GAG GG – 3’ SFRP1 down rev (region 3) 5’ - GAG GGG CGC TGA GCG ATA C – 3’
SFRP3 rev 5’ - CTT ACA TTT ACA GCG TTC ACT GC – 3’ SFRP2 TSS for 5’ - CCG GTG TCC CGC TTC TCC – 3’
SFRP4 for 5' - GCC TTT CCT GTA CCA TCA TGT C - 3' SFRP2 TSS rev 5’ - TCT TCG CTG GGT GCG ACT C – 3’
SFRP4 rev 5' - CCG GAG GAT GTT AAG TGG ATA G - 3' SFRP3 TSS for 5’ - TTG GGA AAG AGC AGC CTG GG – 3’
SFRP5 for 5’ - TGC TCC AGT GAC TTT GTG GTC – 3’ SFRP3 TSS rev 5’ - CTT TAC CGA GCT CCA GCC AC – 3’
SFRP5 rev 5’ - CCC ATT CTC TAT CTT GAT CTC C – 3’ SFRP4 TSS for 5’ - AGC TGC CAA GGG AGC GTT C – 3’
SUZ12 for 5’ - GGG AGA CTA TTC TTG ATG GGA AG - 3’ SFRP4 TSS rev 5’ - CCA TTG CGG GAC CCT ATT TAT C – 3’
SUZ12 rev 5’ - GAG AAA ATG TTT CGA ATG GAG GC - 3’ SFRP5 TSS for 5’ - GAG GAA AAT GCC CAG GGA GG – 3’
SFRP5 TSS rev 5’ - CCT CGC CCA GCG TTT CTC C – 3’
Table S2 Buffers for ChIP
Formaldehyde Solution Lysis buffer * Dilution Buffer* Wash Buffer 1* Wash Buffer 2* Wash Buffer 3* Elution Buffer
1% formaldehyde 50mM Tris/HCl pH 8.0 20mM Tris/HCl pH 8.0 20 mM Tris-HCl pH 8.0 20 mM Tris-HCl pH 8.0 10 mM Tris-HCl pH 8.0 0.1M NaHCO3
4.5mM HEPES pH 8.0 1% SDS 150mM NaCl 150 mM NaCl 500 mM NaCl 0.25 M LiCl 1% SDS
9mM NaCl 5mM EDTA 2mM EDTA 2 mM EDTA 2 mM EDTA 1 mM EDTA
0.09mM EDTA 1% Triton X-100 1% Triton X-100 1% Triton X-100 1% deoxycholate
0.045mM EGTA 0.1% SDS 0.1% SDS 1% NP-40
in PBS
*supplemented with 1x Protease Inhibitor Cocktail (Roche)
 Table S3 Statistical tests
test used student's t-test Mann-Whitney test Wilcoxon signed rank test Pearson's correlation
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